| 1499 |
National Cancer Institute |
Html |
en |
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer. |
| hemiparanasal sinus | 0.501642 |
| cure rates | 0.493854 |
| positive nodes | 0.488668 |
| standard treatment schedules | 0.549584 |
| Nodal involvement | 0.497639 |
| cancer deaths | 0.490757 |
| small percentage | 0.485324 |
| paranasal sinuses | 0.76526 |
| operable tumors | 0.521562 |
| PDQ cancer information | 0.674275 |
| (es). | 0.507032 |
| T1 mucosal carcinomas | 0.579667 |
| neck radiation therapy | 0.604078 |
| cancer information summary | 0.645943 |
| frequent type | 0.494315 |
| high doses | 0.481624 |
| Squamous cell carcinoma | 0.582109 |
| breast cancer prevention | 0.543533 |
| direct extension | 0.48751 |
| malignant degeneration | 0.512598 |
| advanced carcinomas | 0.493525 |
| ethmoid sinuses | 0.558752 |
| NCI’s PDQ | 0.512104 |
| NCI PDQ cancer | 0.582736 |
| paranasal sinus cancers | 0.63814 |
|
| radical surgery | 0.487234 |
| frontal sinuses | 0.560784 |
| radiation therapy | 0.931486 |
| low-grade benign tumor | 0.581394 |
| maxillary sinus | 0.511122 |
| locoregional recurrence accounts | 0.563108 |
| nasal vestibule | 0.506572 |
| Lymph nodes | 0.492664 |
| vital areas | 0.483188 |
| distant metastases | 0.516432 |
| bony confines | 0.499241 |
| malignant tumor | 0.600994 |
| PDQ documents | 0.510902 |
| early tumors | 0.514544 |
| radical radiation therapy | 0.591316 |
| advanced disease | 0.493565 |
| nasal cavity | 0.593061 |
| treatment volume | 0.481814 |
| local disease | 0.484616 |
| tumors | 0.539577 |
| stage III tumors | 0.513203 |
| neck cancer | 0.495811 |
| postoperative radiation therapy | 0.591777 |
| adjacent structures. | 0.488857 |
|
CLICK HERE |
| 1561 |
National Cancer Institute |
Html |
en |
Hairy Cell Leukemia Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of hairy cell leukemia. |
| red blood cells | 0.288652 |
| cancer treatment | 0.275128 |
| following PDQ summaries | 0.252637 |
| PDQ cancer information | 0.3118 |
| clinical trial search | 0.280542 |
| white blood cells | 0.33408 |
| clinical trials | 0.546221 |
| mature blood cells | 0.288256 |
| Natural killer cells | 0.259899 |
| bone marrow cell | 0.248193 |
| cancer information summary | 0.285589 |
| clinical trial | 0.391443 |
| patients | 0.269231 |
| blood cells | 0.357276 |
| earlier clinical trials | 0.248664 |
| Biologic therapy | 0.261621 |
| refractory hairy cell | 0.259547 |
| treatment clinical trial | 0.258654 |
| PDQ Adult Treatment | 0.254235 |
| Cell Leukemia Treatment | 0.279873 |
| NCI PDQ cancer | 0.262149 |
| Treatment Editorial Board | 0.264015 |
| treatment | 0.372653 |
| myeloid stem cell | 0.267967 |
|
| blood stem cell | 0.256899 |
| progressive hairy cell | 0.304412 |
| new cancer treatments | 0.249482 |
| NCI-supported cancer | 0.251402 |
| cancer cells | 0.341635 |
| lymphoid stem cell | 0.268394 |
| laboratory test | 0.252149 |
| Cancer Information Service | 0.24796 |
| specific cancer cells | 0.268675 |
| treatment clinical trials | 0.277379 |
| blood stem cells | 0.287064 |
| National Cancer Institute | 0.286081 |
| normal cells | 0.252914 |
| new treatment | 0.277346 |
| hairy cell leukemia | 0.902024 |
| bone marrow | 0.339709 |
| healthy blood cells | 0.262175 |
| untreated hairy cell | 0.280676 |
| cancer clinical trials | 0.292375 |
| cancer information summaries | 0.250228 |
| comprehensive cancer information | 0.249864 |
| cancer | 0.442493 |
| standard treatment | 0.257771 |
| leukemia cells | 0.29846 |
|
CLICK HERE |
| 1599 |
National Cancer Institute |
Html |
en |
Selected Vegetables/Sun's Soup (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| General Information section | 0.439986 |
| phase I/II | 0.372901 |
| soup | 0.641588 |
| eligible patients | 0.381172 |
| United States | 0.398891 |
| Human/Clinical Studies section | 0.504014 |
| standard laboratory chow | 0.498456 |
| advanced non-small cell | 0.617549 |
| toxicity arm | 0.381025 |
| control group | 0.47167 |
| Sun’s Soup | 0.39938 |
| cell lung cancer. | 0.443882 |
| Soup treatment group. | 0.419226 |
| fed standard laboratory | 0.408383 |
| conventional therapy | 0.380328 |
| Vegetables/Sun’s Soup | 0.633353 |
| dietary supplements | 0.390642 |
| tumor growth | 0.410892 |
| percent body-weight loss | 0.372171 |
| lymph node metastasis | 0.373015 |
| average KPS score | 0.387592 |
| barbat skullcap | 0.397578 |
| cancer information summary | 0.38735 |
| patent document | 0.416332 |
|
| clinical trial | 0.401308 |
| mung bean | 0.484404 |
| barbata D. Don | 0.434127 |
| best supportive care | 0.383219 |
| shiitake mushroom | 0.46504 |
| patients | 0.656235 |
| primary tumor | 0.381698 |
| Selected Vegetables/Sun | 0.926979 |
| Scutellaria barbata D. | 0.437829 |
| KPS score | 0.444385 |
| non-small cell lung | 0.820617 |
| survival arm | 0.438189 |
| Phaseolus radiatus L. | 0.435744 |
| nonconsecutive case series | 0.385568 |
| median survival time | 0.500228 |
| cell lung cancer | 0.65934 |
| study entry | 0.475867 |
| Soup treatment group | 0.54526 |
| radiation therapy | 0.522928 |
| Hedyotis diffusa Willd. | 0.437904 |
| mice fed standard | 0.407302 |
| Soup dietary supplement | 0.400111 |
| I/II clinical trial | 0.398282 |
|
CLICK HERE |
| 1617 |
National Cancer Institute |
Html |
en |
Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms. |
| red blood cells | 0.746761 |
| chronic idiopathic myelofibrosis | 0.40092 |
| cancer treatment | 0.416363 |
| primary myelofibrosis | 0.53957 |
| PDQ cancer information | 0.430215 |
| bone marrow aspiration | 0.385705 |
| clinical trial search | 0.421224 |
| white blood cells | 0.676519 |
| chronic eosinophilic leukemia | 0.451961 |
| blood cells increases | 0.444984 |
| clinical trials | 0.768861 |
| chronic neutrophilic leukemia | 0.40279 |
| mature blood cells | 0.434847 |
| fewer blood cells | 0.406923 |
| cancer information summary | 0.401424 |
| clinical trial | 0.500574 |
| early signs | 0.377313 |
| patients | 0.431687 |
| blood cells | 0.902472 |
| blood vessels | 0.37721 |
| chronic myelogenous leukemia | 0.406738 |
| Treatment Editorial Board | 0.377482 |
| essential thrombocythemia | 0.420345 |
| treatment | 0.55278 |
| stored stem cells | 0.37624 |
|
| immature blood cells | 0.399031 |
| blood stem cell | 0.37725 |
| cancer cells | 0.408902 |
| -fighting blood cells | 0.405086 |
| lymphoid stem cell | 0.374191 |
| specific cancer cells | 0.392312 |
| chronic myeloproliferative neoplasms | 0.69658 |
| signs | 0.38226 |
| polycythemia vera | 0.418683 |
| patient | 0.388228 |
| treatment clinical trials | 0.396123 |
| blood stem cells | 0.497004 |
| National Cancer Institute | 0.457233 |
| routine blood test | 0.45249 |
| new treatment | 0.393316 |
| white blood cell | 0.399685 |
| extra blood cells | 0.469808 |
| bone marrow | 0.605562 |
| PDQ summary | 0.382577 |
| cancer clinical trials | 0.425229 |
| blood clots | 0.392843 |
| cancer | 0.517448 |
| information | 0.439199 |
| Myelogenous Leukemia Treatment | 0.387746 |
|
CLICK HERE |
| 1825 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de hígado infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento cáncer de hígado infantil. |
| liver tumors | 0.936797 |
| Pediatric Oncology | 0.824708 |
| PRETEXT III | 0.10879 |
| Aronson DC | 0.0851201 |
| results from | 0.266716 |
| Paediatric Oncology | 0.0823629 |
| international pediatric liver | 0.110029 |
| Tumor Study Group | 0.204309 |
| standard-risk hepatoblastoma | 0.125193 |
| childhood liver tumors | 0.0905382 |
| Study Group | 0.298822 |
| Maibach R | 0.0922692 |
| hepatocellular carcinoma | 0.861587 |
| International Society | 0.42048 |
| IV hepatoblastoma | 0.218263 |
| Krailo MD | 0.0915991 |
| cog liver tumors | 0.124853 |
| Children's Oncology Group | 0.248758 |
| Estados Unidos | 0.091099 |
| hepatoblastoma with | 0.740659 |
| pediatric liver tumors | 0.222622 |
| hepatoblastoma after chemotherapy | 0.124744 |
| Pediatric Oncology Liver | 0.123326 |
| childhood hepatoblastoma | 0.552956 |
| with hepatoblastoma | 0.638805 |
|
| Perilongo G | 0.171974 |
| PRETEXT IV | 0.0802866 |
| grupos pretext | 0.174753 |
| Group intergroup study | 0.0861929 |
| Pediatr Blood Cancer | 0.319797 |
| Oncology Group study | 0.119848 |
| childhood liver | 0.102417 |
| Japanese Study Group | 0.0968813 |
| report from | 0.211803 |
| Childrens Cancer Study | 0.0958008 |
| quimioterapia preoperatoria | 0.196007 |
| Hepatoblastoma presenting with | 0.134427 |
| Liver Tumor Study | 0.217304 |
| Pediatr Surg | 0.270609 |
| Clin Oncol | 0.979661 |
| Hepatoblastoma metastatic | 0.11507 |
| Otte JB | 0.0939222 |
| Children's Cancer Group | 0.202883 |
| Shafford E | 0.259892 |
| prospective study | 0.154606 |
| Oncology Liver Tumor | 0.132492 |
| pediatric oncology group | 0.588258 |
| oncology group | 0.803949 |
| Cancer Study Group | 0.108904 |
|
CLICK HERE |
| 1879 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) en el embarazo. |
| Chua T | 0.308433 |
| Rugo HS | 0.308741 |
| exposed to chemotherapy | 0.30311 |
| Surg Gynecol Obstet | 0.330452 |
| outcome after | 0.304299 |
| pregnant patient | 0.315879 |
| anomalÃas congénitas | 0.308598 |
| Clark RM | 0.307911 |
| Theriault R | 0.32478 |
| cancer diagnosed during | 0.342035 |
| diagnosed during pregnancy | 0.34332 |
| Loprinzi CL | 0.304379 |
| Sin embargo | 0.313532 |
| patient with carcinoma | 0.318411 |
| mother during gestation | 0.303218 |
| Instituto Nacional | 0.305213 |
| Petrek JA | 0.304025 |
| Yang WT | 0.304051 |
| breast carcinoma during | 0.308603 |
| breast carcinoma | 0.313568 |
| Gynecol Oncol | 0.302701 |
| altas concentraciones | 0.304242 |
| cancer diagnosed | 0.35036 |
| safety after breast | 0.308046 |
| chemotherapy during pregnancy | 0.3192 |
|
| Curr Treat Options | 0.317342 |
| administration during pregnancy | 0.307821 |
| overall survival after | 0.302827 |
| R Coll Radiol | 0.316078 |
| Wallack MK | 0.309132 |
| Gallenberg MM | 0.304139 |
| ultimate challenge | 0.308285 |
| Surg Clin North | 0.303453 |
| National Cancer Institute | 0.306047 |
| during pregnancy | 0.532041 |
| Surg Oncol | 0.303192 |
| pregnant patient with | 0.318156 |
| PDQ Tratamiento | 0.303689 |
| after maternal cancer | 0.306691 |
| Clin Oncol | 0.325015 |
| Radiotherapy during pregnancy | 0.307723 |
| breast cancer | 0.976679 |
| systematic review | 0.303372 |
| Treat Options Oncol | 0.318121 |
| Dryden MJ | 0.304024 |
| breast cancers from | 0.308506 |
| with or without | 0.302892 |
| as systemic treatment | 0.302539 |
| Gwyn K | 0.36898 |
|
CLICK HERE |
| 1911 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de células renales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de células renales. |
| siguientes procedimientos | 0.302667 |
| mal uso | 0.302989 |
| siguientes aspectos | 0.301319 |
| estadio ii | 0.309628 |
| túbulos renales | 0.304796 |
| pequeños trozos | 0.300679 |
| siguientes tipos | 0.302146 |
| Renal Cell | 0.303601 |
| rayos x | 0.302568 |
| sistema urinario masculino | 0.3018 |
| enlace drugs approved | 0.306606 |
| riñón sano donado | 0.303031 |
| National Cancer Institute | 0.300453 |
| siguientes riesgos | 0.300391 |
| realidad células | 0.303887 |
|
| pelvis renal | 0.306725 |
| Instituto Nacional | 0.301826 |
| PDQ Tratamiento | 0.304405 |
| Physician Data Query | 0.301827 |
| nefrectomÃa radical | 0.310748 |
| pequeña incisión | 0.300747 |
| tumor mide | 0.303146 |
| von hippel-lindau | 0.30106 |
| vejiga almacena | 0.301249 |
| pequeños túbulos | 0.301281 |
| siguientes enlaces | 0.300545 |
| células renales | 0.988263 |
| riesgo cáncer | 0.31289 |
| siguientes pruebas | 0.301322 |
| vasos sanguÃneos | 0.317262 |
|
CLICK HERE |
| 3440 |
National Cancer Institute |
Html |
es |
Exámenes de detección del neuroblastoma (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma. |
| Visuals Online | 0.563675 |
| PDQ Exámenes | 0.77452 |
| Physician Data Query | 0.971175 |
| ecografÃa fetal | 0.642315 |
| prevención revisa | 0.581226 |
| graves riesgos | 0.622769 |
|
| presente sÃntomas | 0.605798 |
| información ayuda | 0.590632 |
| cuáles tipos | 0.60865 |
| National Cancer Institute | 0.613572 |
| siguientes riesgos | 0.582879 |
| Instituto Nacional | 0.71673 |
|
CLICK HERE |
| 4337 |
National Cancer Institute |
Html |
en |
Appetite Loss and Cancer Treatment |
Cancer treatments may lower your appetite. Side effects such as nausea, fatigue, or mouth sores can also making eating difficult. Learn how to eat well to avoid losing weight or becoming dehydrated, so you stay strong during treatment. |
| Care PDQ® summary | 0.905921 |
| questions | 0.493671 |
| liquids | 0.644562 |
| dietitian | 0.466542 |
| short walk | 0.691875 |
| health care team | 0.956003 |
| professional version | 0.683094 |
| variety | 0.451735 |
| causes | 0.450224 |
| nurse | 0.455725 |
| Prepare | 0.451462 |
| dehydration | 0.472596 |
| throat problems | 0.73358 |
| drink choices | 0.682925 |
| vomiting | 0.475861 |
| food tastes | 0.745638 |
| Cancer treatments | 0.729931 |
| cancer patients | 0.671489 |
| supplemental nutrition drinks | 0.886258 |
| weight | 0.457616 |
| large meals | 0.701392 |
| plenty | 0.541422 |
|
| calories | 0.468062 |
| list | 0.493655 |
| eating | 0.456684 |
| steps | 0.457353 |
| people | 0.451814 |
| dangerous condition | 0.706738 |
| small meals | 0.702125 |
| way | 0.460708 |
| nausea | 0.479468 |
| nutritional problems | 0.667746 |
| doctor | 0.457447 |
| symptoms | 0.451468 |
| supplements | 0.451833 |
| Cancer-related fatigue | 0.794241 |
| effects | 0.460377 |
| mouth | 0.464482 |
| vitamins | 0.459091 |
| NCI | 0.456663 |
| high-nutrient foods | 0.702331 |
| appetite | 0.964964 |
| information | 0.45027 |
| nutrient-dense foods | 0.715035 |
|
CLICK HERE |
| 16826 |
National Cancer Institute |
Html |
en |
Early Onset Malignancies Initiative |
The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations. |
| community sites | 0.48513 |
| control group | 0.496806 |
| certain minority populations | 0.77365 |
| exome sequencing | 0.513318 |
| ethnic populations | 0.59564 |
| ethnic groups | 0.477288 |
| multiple platforms | 0.483426 |
| early detection | 0.483135 |
| tumor behavior | 0.507221 |
| cutting-edge genomic characterization | 0.794697 |
| early age | 0.515521 |
| genomic datasets | 0.554094 |
| patient populations | 0.708455 |
| multiple myeloma | 0.479782 |
| critical research | 0.469762 |
| rich genomic data | 0.741156 |
| cancer types | 0.666255 |
| Thorough clinical data | 0.657553 |
| extensive data | 0.513023 |
| clinical measures | 0.479008 |
| molecular targets | 0.47719 |
| TCGA | 0.415616 |
| tumor progression | 0.525349 |
| earlier age | 0.508182 |
|
| higher rates | 0.504515 |
| important insights | 0.491579 |
| molecular drivers | 0.46961 |
| cancer type | 0.492461 |
| NCI Genome Characterization | 0.808398 |
| early disease | 0.497354 |
| clinical updates | 0.489197 |
| disease monitoring | 0.476658 |
| Genome Characterization Pipeline | 0.932301 |
| collaborative initiative | 0.505734 |
| NCI genomic characterization | 0.824673 |
| EOMI | 0.680345 |
| NCI Community Oncology | 0.754977 |
| total RNA sequencing | 0.668278 |
| underrepresented minorities | 0.53639 |
| Cancer Genome Atlas | 0.669216 |
| tissue samples | 0.659999 |
| Early Onset Malignancies | 0.747146 |
| EOMI data | 0.528397 |
| treatment response | 0.492799 |
| cancer risk | 0.496991 |
| genome sequencing | 0.549082 |
| Cancer Prevention | 0.5334 |
| normal tissue samples | 0.654735 |
|
CLICK HERE |